Aktienanalyse zu Sarepta Therapeutics Inc (SRPT)SRPTSarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sarepta Therapeutics Inc is currently trading at $17.10, which is below the average analyst price target of $20, indicating potential upside. However, the RSI is at 42.01, suggesting the stock is nearing oversold conditions but not yet in a strong buy zone. The company has shown a gross margin of 85.02% in Q1 2026, indicating strong profitability, but it has faced significant revenue declines, with a 25.81% drop in the past year. The main risk is the hedge fund selling activity, which has increased by 12693.27% over the last quarter, indicating a lack of confidence from institutional investors. Therefore, while there are some positive indicators, the overall sentiment and selling pressure suggest holding off on buying for now.

18 analysts cover SRPT: 17 rate it Buy, 1 Hold and 0 Sell. The average price target is 20.80.